AuntMinnie
DECEMBER 19, 2023
Conversely, recently developed portable PET scanners include seated or standing configurations and have been proposed for use in combat zones, sports fields, and intensive care units, the researchers added. In 2018, the group received a grant from the U.S. A link to the full study can be found here.
Imaging Technology
JUNE 15, 2023
Further information available at clinicaltrials.gov - ClinicalTrials.gov Identifier: NCT05629689 - A Study to Evaluate GEH200520/GEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies 3. Fruhwirth, G. Kneilling, M., De Vries, I. Weigelin, B., Srinivas, M., & Aarntzen, E.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
MAY 31, 2023
[iii] Based on orders data of GE HealthCare PET/CT systems since 2010. [iv] Measurement follows NEMA NU 2-2018. [v] v] Up to 53% reduction of PET scan time on Omni Legend 32 cm compared to Discovery MI 25 cm, as demonstrated in phantom testing. [vi] iv] Omni Legend 32 cm has up to 2.2 ix Mehranian, A., Walker, M.D.
AuntMinnie
MARCH 26, 2024
This theranostic therapy first demonstrated how using diagnostic imaging with a radioactive probe, gallium-68 (Ga-68 dotatate injection), could locate NETs on PET scans. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
AuntMinnie
JUNE 20, 2024
This theranostic therapy first demonstrated how using diagnostic imaging with a radioactive probe, gallium-68 (Ga-68 dotatate injection), could locate NETs on PET scans. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
Imaging Technology
MAY 30, 2023
Results demonstrated high detection rates (% positive PET scans) even at low PSA levels. Food and Drug Administration approval for its radiohybrid PET diagnostic imaging product for use in prostate cancer in 2023. In clinical trials , the safety of POSLUMA was evaluated in 747 patients with initial or recurrent prostate cancer.
Imaging Technology
MAY 2, 2023
For example, results showed that among the subgroup (n=76) of patients in the Evaluable PET Scan Population who had undergone primary treatment with radiation therapy for prostate cancer, the overall patient-level DR was 99% (75/76) and consistently high across the three independent readers (range 93-99%).
Expert insights. Personalized for you.
122 
Let's personalize your content